FOXA1 and lung adenocarcinoma: For example, in small cell lung cancer (SCLC), a neuroendocrine lung cancer variant that can emerge de novo or from EGFR-mutant lung adenocarcinoma after targeted kinase inhibition, FOXA1 is highly expressed and encompassed by a super-enhancer31.